Avidity Biosciences
Antibody Oligonucleotide Conjugates (AOC) platform for targeted RNA therapeutics
- Sector
- Biotech
- Headquarters
- San Diego, CA
- Founded
- 2012
- Latest Form D
- $400M, Mar 2024
- Total capital
- $528M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $528M
- 4 Form D · last Mar 2024
- 31 months since last filing
- Federal contracts
- $200K
- 1 award · Health and Human S
- Rank in Biotech#293 of 4373
- Granted patents
- 20
- 20 pending · first 2024
- Rank in peer group#32 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$400M
- Private capital raisedForm D · SEC · 3rd filing$101M
- Private capital raisedForm D · SEC · 2nd filing$18M
- Private capital raisedForm D · SEC · 1st filing$9.1M
- Federal contractHealth and Human S · Igf::ot::igf$200K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
5months
from Avidity Biosciences’s first federal award to its first private round.
- First federal award · Sep 2013
- Health and Human S · $200K
- First Form D · Feb 2014
- $9.1M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#32 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Arthur LevinExecutive OfficerNamed in SEC Form D filings
- Carsten Michael BoessDirectorNamed in SEC Form D filings
- Edward Michael KayeDirectorNamed in SEC Form D filings
- Jean Michael KimDirectorNamed in SEC Form D filings
- Michael Michael MacLeanExecutive OfficerNamed in SEC Form D filings
- MICHAEL MARTINDirectorNamed in SEC Form D filings
Show all 17 people
- Michael Martin PhD.DirectorNamed in SEC Form D filings
- Noreen Michael HenigDirectorNamed in SEC Form D filings
- P. Kent HawrylukExecutive OfficerNamed in SEC Form D filings
- RODERICK WONGDirectorNamed in SEC Form D filings
- Sarah BoyceExecutive Officer, DirectorNamed in SEC Form D filings
- Tamar Michael ThompsonDirectorNamed in SEC Form D filings
- Teresa Michael McCarthyExecutive OfficerNamed in SEC Form D filings
- Todd BradyDirectorNamed in SEC Form D filings
- TROY WILSONDirectorNamed in SEC Form D filings
- Troy Wilson PhD., JDExecutive Officer, DirectorNamed in SEC Form D filings
- W. Michael FlanaganExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 20 granted of 40- PendingNovel Preparation Of Oligonucleotide Conjugates Using Transition Metals Or Salts ThereofUSPTOApplication 19425930
- PendingCompositions And Methods Of Treating Muscle DystrophyUSPTOApplication 19668501
- PendingConjugate Compositions Comprising Phosphoryl Guanidine Linkages And Uses ThereofUSPTOApplication 19405243
Show all 40 patent records
- Novel Preparation Of Oligonucleotide Conjugates Using Transition Metals Or Salts ThereofSep 3, 2026 · Application 19425930Pending
- Compositions And Methods Of Treating Muscle DystrophyAug 27, 2026 · Application 19668501Pending
- Conjugate Compositions Comprising Phosphoryl Guanidine Linkages And Uses ThereofAug 27, 2026 · Application 19405243Pending
- Anti-transferrin Receptor Antibody-pmo Conjugates For Inducing Dmd Exon 44 SkippingJun 9, 2026 · US 12,648,998Granted
- Compositions And Methods Of Treating Muscle DystrophyJun 9, 2026 · US 12,648,999Granted
- Nucleic Acid-polypeptide Compositions And Methods Of Inducing Exon SkippingMar 5, 2026 · Application 19312209Pending
- Compositions And Methods Of Treating Facioscapulohumeral Muscular DystrophyJan 20, 2026 · US 12,529,056Granted
- Compositions And Methods Of Treating Muscle DystrophyJan 15, 2026 · Application 19263372Pending
- Anti-transferrin Receptor Antibody-pmo Conjugates For Inducing Dmd Exon 44 SkippingJan 8, 2026 · Application 19329403Pending
- Compositions And Methods Of Treating Muscle Atrophy And Myotonic DystrophyJan 8, 2026 · Application 19331924Pending
- Nucleic Acid-polypeptide Compositions And Methods Of Inducing Exon SkippingDec 18, 2025 · Application 19311956Pending
- Nucleic Acid Compositions And Methods Of Multi-exon SkippingDec 16, 2025 · US 12,497,615Granted
- Compositions And Methods Of Using PRKAG2-TARGETING Antibody-oligonucleotide ConjugatesDec 9, 2025 · US 12,491,257Granted
- Compositions And Methods Of Treating Facioscapulohumeral Muscular DystrophyDec 2, 2025 · US 12,486,328Granted
- Compositions And Methods Of Treating Facioscapulohumeral Muscular DystrophyNov 6, 2025 · Application 19267387Pending
- Antibody-oligonucleotide Conjugate Compositions And Methods Of Inducing Dmd Exon 50 SkippingOct 23, 2025 · Application 19097573Pending
- Antibody-oligonucleotide Conjugate Compositions And Methods Of Inducing Dmd Exon 52 SkippingOct 23, 2025 · Application 19097593Pending
- Antibody-oligonucleotide Conjugate And Antibody-peptide-oligonucleotide Conjugate Compositions And Methods Of Inducing Exon SkippingOct 2, 2025 · Application 18553134Pending
- Compositions And Methods Of Treating Muscle DystrophySep 30, 2025 · US 12,427,202Granted
- Compositions Comprising Pln-targeting Anti-transferrin Receptor Antibody-polynucleotides And Methods Of Use Thereof To Treat CardiomyopathySep 9, 2025 · US 12,409,230Granted
- Nucleic Acid-polypeptide Compositions And Uses ThereofJul 22, 2025 · US 12,364,769Granted
- Nucleic Acid-polypeptide Compositions And Uses ThereofJul 22, 2025 · US 12,365,704Granted
- Anti-transferrin Receptor Antibody-pmo Conjugates For Inducing Dmd Exon 44 SkippingJul 15, 2025 · US 12,359,202Granted
- Nucleic Acid-polypeptide Compositions And Uses ThereofJul 8, 2025 · US 12,351,637Granted
- COMPOSITIONS AND METHODS FOR MODULATING NaV1.8Jun 26, 2025 · Application 18976126Pending
- Compositions And Methods Of Treating Muscle Atrophy And Myotonic DystrophyJun 19, 2025 · Application 19031255Pending
- Nucleic Acid-polypeptide Compositions And Methods Of Inducing Exon SkippingMay 29, 2025 · Application 19031269Pending
- Nucleic Acid-polypeptide Compositions And Methods Of Inducing Exon SkippingMay 22, 2025 · Application 19031231Pending
- Antibody-oligonucleotide Conjugate Compositions And Methods Of Inducing Dmd Exon 45 SkippingApr 17, 2025 · Application 18903935Pending
- Compositions And Methods Of Treating Muscle Atrophy And Myotonic DystrophyApr 1, 2025 · US 12,263,224Granted
- Nucleic Acid-polypeptide Compositions And Uses ThereofFeb 25, 2025 · US 12,234,290Granted
- Compositions And Methods Of Treating Facioscapulohumeral Muscular DystrophyDec 5, 2024 · Application 18809215Pending
- Compositions And Methods Of Treating Facioscapulohumeral Muscular DystrophyDec 3, 2024 · US 12,157,774Granted
- Nucleic Acid-polypeptide Compositions And Methods Of Inducing Exon SkippingOct 31, 2024 · Application 18770359Pending
- Compositions And Methods Of Treating Facioscapulohumeral Muscular DystrophyOct 1, 2024 · US 12,104,156Granted
- Compositions And Methods Of Treating Facioscapulohumeral Muscular DystrophyAug 29, 2024 · Application 18637337Pending
- Anti-transferrin Receptor Antibody-pmo Conjugates For Inducing Dmd Exon 44 SkippingAug 27, 2024 · US 12,071,621Granted
- Compositions And Methods Of Treating Facioscapulohumeral Muscular DystrophyAug 27, 2024 · US 12,071,485Granted
- Nucleic Acid-polypeptide Compositions And Methods Of Inducing Exon SkippingAug 20, 2024 · US 12,064,483Granted
- Compositions And Methods Of Treating Facioscapulohumeral Muscular DystrophyJul 30, 2024 · US 12,049,629Granted
Related companies, and why
- Edesa Biotech, Inc.Similar federal contract value in Biotech · $214K in contracts
- THE TINY CARGO COMPANYSimilar federal contract value in Biotech · $210K in contracts
- Ursa AnalyticsSimilar federal contract value in Biotech · $205K in contracts
- TARGEPEUTICS, INC.Similar federal contract value in Biotech · $200K in contracts
- Celldex TherapeuticsSimilar federal contract value in Biotech · $199K in contracts
- Aura BiosciencesSimilar federal contract value in Biotech · $198K in contracts
Press
Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test FierceBiotech
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .